Abstract: ob＜x＞jective: To analyse clinical effectiveness and security of azithromycin sequential therapy combined with terbutaline in the treatment of mycoplasma pneumonia by compare. Methods: The subjects of this study were 60 children with mycoplasma pneumonia admitted to our hospital from September 2017 to July 2018,Patients were divided into observation group and control group according to the random number method, with 30 cases each. Patients in the observation group were given sequential treatment of azithromycin combined with nebutamine inhalation, and patients in the control group were given erythromycin intravenous infusion therapy combined with nebutamine inhalation, Clinical efficacy and safety of the two groups were compared, That is, the disappearance time and adverse reactions of related clinical manifestations after treatment (cough, fever, wheezing, lung rumble) , as well as before and after treatment serum tumor necrosis factor alpha (TNF -α), interleukin 6 (IL-6) - cytokines such as the change of the level. Results: The total effective treatment rate for the observation group was 90.00%, the control group was 80.00%, and the difference was no statistically significant (χ2 =0.16，P=0.69); the disappearance time of cough, fever, wheezing and lung rumble was shorter in the observation group than in the control group, and the difference was no statistically significant (P>0.05); in the two groups after treatment in patients with serum TNF-α, IL-6 were significantly lower, comparative differences was no statistically significant (P>0.05); the total incidence of adverse reactions was 13.33% in the observation group and 36.67% in the control group;the difference between the two groups was statistically significant(χ2=4.36,P=0.04). Results: For the treatment of mycoplasma pneumonia in children, azithromycin sequential therapy combined with terbutaline atomization inhalation therapy has a significant effect, significantly improving the cytokine level of the patients, rapidly alleviating the clinical symptoms of the patients, and has a higher safety.Key words: Azithromycin; Terbutaline; Sequential Therapy; Mycoplasma Pneumonia